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The NHS in England offers routine cervical 
screening to females aged 25–64 years. 
Screening starts at the age of 25 years, 
based on evidence that harms outweigh 
benefits in females <25 years.1 The policy 
on the timing of the first invitation has been 
controversial, with many calling for females 
to be invited at a younger age. Females in 
Scotland (and, until recently, in Wales) are 
still invited from age 20 years. In 2009 the 
policy was reviewed, and retained, after 
public and professional debate around the 
time of the death of the celebrity Jade 
Goody from cervical cancer at the age of 27.
After this debate, the English Advisory 
Committee on Cervical Screening 
recommended that the routes to diagnosis 
and duration of symptoms in young patients 
with symptomatic cervical cancer be 
audited. This was based on case reports 
from clinicians and patients2,3 that delayed 
diagnosis resulted from failure (among 
patients and health professionals) to 
recognise the seriousness of symptoms, 
rather than from not being screened.4
The most common symptoms of 
cervical cancer are postcoital bleeding, 
intermenstrual bleeding, and vaginal 
discharge;5–9 however, these are 
common in young females with non-
malignant conditions (for example, 
genital infections)6,10,11 or taking hormonal 
contraceptives. Furthermore, cervical 
cancer is very rare in young females: 353 
females aged 25–29 years and 47 aged 
20–24 years were diagnosed in 2011 in 
England.12
This study aimed to collect data on 
nature and duration of symptoms and 
risk factors for delay in presentation and 
diagnosis in young females with cervical 
cancer. This was intended to inform 
approaches to promote early presentation 
and prompt referral among young females 
with symptoms of cervical cancer.
METHOD
Study participants
The participants were females aged 
18–29 years and diagnosed in England 
with cervical cancer during 2011 and 
2012. Patients aged 25–29 years were 
included because many are diagnosed via 
symptomatic presentation13 (screening 
coverage is low (~60%).14 Patients were 
excluded if they required an interpreter, 
or were inappropriate to interview (for 
example, if they had mental health issues).
Between April 2011 and March 2012, 
patients were prospectively identified by 
asking pathology laboratories and gynae-
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Abstract
Background
Diagnosis may be delayed in young females 
with cervical cancer because of a failure to 
recognise symptoms.
Aim
To examine the extent and determinants of 
delays in diagnosis of young females with 
symptomatic cervical cancer.
Design and setting
A national descriptive study of time from 
symptoms to diagnosis of cervical cancer 
and risk factors for delay in diagnosis at 
all hospitals diagnosing cervical cancer in 
England.
Method
One-hundred and twenty-eight patients 
<30 years with a recent diagnosis of cervical 
cancer were interviewed. Patient delay was 
defined as ö3 months from symptom onset 
to first presentation and provider delay as 
ö3 months from first presentation to diagnosis.
Results
Forty (31%) patients had presented 
symptomatically: 11 (28%) delayed 
presentation. Patient delay was more common 
in patients <25 than patients aged 25–29 (40% 
versus 15%, P = 0.16). Vaginal discharge was 
more common among patients who delayed 
presentation than those who did not; many 
reported not recognising this as a possible 
cancer symptom. Provider delay was reported 
by 24/40 (60%); in some no report was found 
in primary care records of a visual inspection 
of the cervix and some did not re-attend after 
the first presentation for several months. 
Gynaecological symptoms were common (84%) 
among patients who presented via screening. 
Conclusions
Young females with cervical cancer frequently 
delay presentation, and not recognising 
symptoms as serious may increase the risk of 
delay. Delay in diagnosis after first presentation 
is also common. There is some evidence that 
UK guidelines for managing young females 
with abnormal bleeding are not being followed.
Keywords
cervical cancer; delays; early diagnosis; 
symptoms; young females.
Anita W Lim, Amanda J Ramirez, William Hamilton, Peter Sasieni, Julietta Patnick  
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oncology clinical teams in all NHS hospitals 
diagnosing cervical cancer in England to 
notify the study investigators of eligible 
cases. The study was also publicised using 
cancer charity websites, so that patients 
could volunteer to take part directly. 
Diagnosis was confirmed for all patients by 
the pathology laboratory or clinical team. 
Each patient’s clinical team was asked to 
assess eligibility and invite her to take part. 
For patients providing specific consent, 
primary care records were requested for 
the 2 years before diagnosis, plus results of 
cervical screening tests from the National 
Cervical Screening Database.
Measures
Data were collected using a semi-structured 
interview-based measure (the interview 
schedule is available from the authors on 
request).15 This approach has advantages 
over collecting data from medical records 
or using self-completion questionnaires, 
because it allows the interviewer to clarify 
and check the sequence of events, and to 
probe for information that patients might 
not consider relevant.16
The measure collects data about dates 
of symptoms and healthcare attendances 
from the first possible cancer symptom 
through to diagnosis and risk factors for 
delay in presentation.
Data collection
The same trained interviewer conducted 
all the interviews either face-to-face or on 
the telephone (according to the patients’ 
preference) within 2–6 months of diagnosis. 
Interviews were audiorecorded for quality 
assurance and data checking.
Analysis
Characteristics (age, stage [using the 
International Federation of Gynecology and 
Obstetrics {FIGO} classification], histology, 
and geographical region) of patients who 
were interviewed were compared with 
those who were not, and of notified cases 
and patients aged 18–29 years with cervical 
cancer recorded in the National Cancer 
Registration Dataset in 2010 (Appendix 1).
Patients were categorised according to 
whether they had been diagnosed via:
1. Symptomatic presentation: if they had 
presented to a health professional 
with one or more symptoms from a 
checklist of possible symptoms of 
cervical cancer5–9,17–19 (Box 1) and that 
presentation led to diagnosis (including 
patients diagnosed via abnormal cytology 
if the test was done for diagnostic 
purposes).
2. Abnormality detected on NHS Cervical 
Screening Programme: if they were 
diagnosed as a result of a finding during 
a routine cervical screening test after an 
invitation on the NHS Cervical Screening 
Programme.
3. Incidental finding: if they were diagnosed 
during management of an unrelated 
condition. 
Date of diagnosis was defined as the 
date the patient said she was told she had 
cervical cancer.20 For patients diagnosed 
via symptomatic presentation, the ‘trigger’ 
symptom was identified, defined as the 
earliest symptom from the checklist in 
Box 1 that led the patient to present to a 
health professional and led to diagnosis. For 
all patients, the symptom that she believed 
to be the first symptom of her cancer 
was identified at the time of interview (the 
‘first attributed’ symptom) and the earliest 
symptom from the checklist that the patient 
reported, but did not attribute to cervical 
cancer at the time of the interview (the 
‘initial’ symptom).
Patient duration of symptoms from onset 
to first attendance with the trigger symptom 
was calculated, and provider duration of 
symptoms from first attendance with trigger 
symptom to diagnosis, rounding to the 
nearest month. Delayed presentation was 
defined as patient duration of symptoms of 
ö3 months (a cut-off point that is convention 
in studies of this nature21–23), and provider 
delay as provider duration of symptoms of 
ö3 months. Primary care delay was defined 
as referral ö6 weeks after first attendance 
and secondary care delay as diagnosis 
ö6 weeks after referral.
For patients who presented via 
symptomatic presentation and reported 
provider delay, the general practice 
records were examined (including free 
text). Whenever possible, the period in the 
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How this fits in
There have been reports that young 
females with cervical cancer experience 
delays in diagnosis because of a failure 
to recognise symptoms. This study has 
found that a high proportion of patients 
aged <30 years with symptomatic cervical 
cancer delay presentation. Delay in referral 
after presentation is also common. There 
is some evidence that the UK guidelines for 
managing young females with abnormal 
bleeding are not being followed.
Box 1. Cervical cancer 
symptom checklist
• Bleeding after sex 5–9,17–19
• Bleeding between periods 7,9,17,19
• Change in periods 5
• Bleeding during pregnancy
• Painful sex
• Persistent vaginal discharge 5,6,9,18,19
• Abdominal or pelvic pain or discomfort 7,9,19
• Unusual fatigue
primary care records which matched the 
period described at interview, in terms of 
symptoms and date of attendance (within 
3 months of the date reported by the patient), 
was identified. Records were examined for 
documented evidence of visualisation of the 
cervix, tests for genital infection, or cervical 
cytology. Dates of referral were extracted 
and used to calculate time from first 
attendance to referral and from referral to 
diagnosis.
For patients aged 25–29 years diagnosed 
via symptomatic presentation, cervical 
screening history was examined in the 
national database to find out whether they 
had been screened and, if so, how long 
before the presentation, and the result(s).
Odds ratios and 95% confidence 
intervals (CIs) were calculated to evaluate 
the association between possible risk 
factors for delay (Box 2), treated as binary 
categorical variables, and delay status. 
The r2 test or Fisher’s exact test (when 
the expected cell frequency was <5) were 
used to assess differences between delays 
and symptom characteristics between age 
groups and pathways to diagnosis.
All statistical analyses were performed 
using Stata Statistical Software (Release 
12). A P-value of <0.05 was considered 
statistically significant. All statistical tests 
were two-sided.
RESULTS
One-hundred and sixteen hospitals 
identified 333 patients (237 from pathology 
laboratories and 96 from clinical teams) over 
an average recruitment period of 8 months 
(range 1–11 months). One additional patient 
volunteered to take part after seeing the 
study on a charity website. Within the study 
period, 286 (86%) patients were invited; 164 
agreed, and 128 (38% of eligible patients 
identified) were interviewed. Mean time 
from diagnosis to interview was 4.3 months 
(range 1.0–8.5 months).
Characteristics of patients identified who 
were interviewed versus not interviewed 
were comparable, although interviewed 
patients were younger and more had 
adenocarcinoma (Appendix 1). Patients 
identified were broadly representative of 
patients identified nationally by the cancer 
registry for age, stage, histology, and 
geographical region.
Twenty-two (17%) patients interviewed 
were aged <25 years. Most were of white 
ethnic origin, and most had a partner or 
husband (Table 1). Sixty-two (48%) had 
children and 32 (25%) had left full-time 
education at age õ16 years. Sixty-seven 
patients (52%) had microinvasive cancer 
(that is, stage 1a). Ninety-three (73%) 
had squamous cell carcinoma, 28 (22%) 
adenocarcinoma, and seven (6%) other 
histology.
Of the 22 patients <25 years, one was 
diagnosed after a cervical lesion was seen 
during intrauterine device removal and 
another via screening (just before her 25th 
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Box 2. Putative risk factors for patient and provider delay
Risk factors for patient delay
• Nature of the trigger symptom
• Having children
• Having left full-time education aged õ16 years
• Using hormonal or intrauterine contraception
• Pregnancy
• Not thinking the symptom was serious at the time
• Not knowing what the symptoms of cervical cancer were before diagnosis
• Barriers to symptomatic presentation including:
 • feeling too embarrassed
 • finding it difficult to get an appointment
 • being too busy to make an appointment
 • worrying about not seeing a female doctor
 • worrying about what the GP might find
 • not wanting to waste the GP’s time
Risk factors for provider delay
• Nature of the trigger symptom
• Pregnancy
• Using hormonal or intrauterine contraception
Table 1. Demographic and clinical characteristics of interviewed 
patients
 Patients aged Patients aged All patients 
 18–24 years  25–29 years (n  = 128), 
 (n  = 22), n (%) (n  = 106), n (%) n (%)
Ethnicity 
 White 22 (100) 99 (93.4) 121 (94.5)
Age left full-time education, years 
 15–16 8 (36.4) 24 (22.6) 32 (25.0) 
 17–18 7 (31.8) 38 (35.8) 45 (35.2) 
 ö19 or still studying 7 (31.8) 44 (41.5) 51 (39.8)
Had a partner/husband 21 (95.5) 90 (84.9) 111 (86.7)
Had children 13 (59.1) 48 (45.3) 61 (47.7)
FIGO stage 
 1a 5 (22.7) 62 (58.5) 67 (52.3) 
 1b 13 (59.1) 40 (37.7) 53 (41.4) 
 2 2 (9.1) 3 (2.8) 5 (3.9) 
 3 2 (9.1) 1 (0.9) 3 (2.3) 
 4 – – –
Histology 
 Squamous 16 (72.7) 77 (72.6) 93 (72.7) 
 Adenocarcinoma 4 (18.2) 24 (22.6) 28 (21.9) 
 Other 2 (9.1) 5 (4.7) 7 (5.5)
FIGO = International Federation of Gynecology and Obstetrics.
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birthday); all the others were diagnosed 
via symptomatic presentation. Of the 106 
patients aged 25–29 years, 85 (80%) were 
diagnosed via an abnormality detected on 
the NHS Cervical Screening Programme, 
20 (19%) were diagnosed via symptomatic 
presentation, and one was diagnosed after 
a cervical lesion was seen during insertion 
of an intrauterine device.
Patients diagnosed via symptomatic 
presentation
Of the 40 patients diagnosed via symptomatic 
presentation, 11 (28%) reported patient 
delay, and 24 (60%) reported provider 
delay (Table 2). The most common trigger 
symptom (33/40) was abnormal vaginal 
bleeding, with 19 patients describing 
postcoital bleeding (Table 3).
Twenty-three patients (56%) reported 
earlier symptoms that had not prompted 
help-seeking: 10 attributing these 
symptoms to cancer at the time of interview 
(six with abnormal vaginal bleeding); and 
13 not attributing them to cancer at the 
time of interview, most commonly vaginal 
discharge (n = 6).
Patients aged 18–24 years. Among the 
20 patients aged <25 years diagnosed via 
symptomatic presentation, 16 (80%) had at 
least stage 1b cancer. 
The median duration of symptoms 
from the trigger symptom to presentation 
was 2.0 months (interquartile range [IQR] 
0.5–4.5 months); 8/20 (40%) had delayed 
presentation. The median provider duration 
of symptoms was 3.0 months (IQR 2.0–
8.5 months); 10/20 (50%) reported provider 
delay.
Patients aged 25–29 years. Of the 20 
patients aged 25–29 years diagnosed via 
symptomatic presentation, 12 (60%) had at 
least stage 1b cancer.
Five patients had been diagnosed as a 
result of abnormal cytology on a diagnostic 
test after symptomatic presentation. None 
of these patients had ever attended for 
cervical screening after a routine invitation.
The median patient duration of symptoms 
from the trigger symptom was 1.0 month 
(IQR 0–2.0 months). Fewer patients 3/20 
(15%) delayed presentation in comparison 
with the patients aged <25 years (40%, 
P = 0.16). The median provider duration 
of symptoms was 6.0 months (IQR 2.5–
9.5 months); 14/20 (70%) reported provider 
delay (Table 2).
Sixteen (80%) of the 20 patients aged 
25–29 years with symptomatic presentation 
consented to access of their screening data. 
Nine (56%) had attended routine screening 
within the 3.5 years before diagnosis (that 
is, were interval cancers), and the rest 
had never been screened. Of the screened 
patients, only one had had abnormal 
cytology but findings had been normal on 
a subsequent colposcopy 16 months before 
diagnosis. 
Risk factors for delayed diagnosis among 
patients diagnosed via symptomatic 
presentation. Table 4 shows the frequency 
of possible risk factors for delays. None of 
the differences were statistically significant. 
The largest odds ratio for patient delay, 
however, was for not knowing what the 
symptoms of cervical cancer were. For 
provider delay this was using hormonal or 
intrauterine contraception. 
Explaining provider delays among 
patients who presented symptomatically
Primary care records were received for 
21/24 patients who reported a provider 
Table 2. Patient and provider delay for patients diagnosed via 
symptomatic presentation
 Patients aged Patients aged All patients 
 18–24 years aged 25–29 years (N = 40), 
 (N = 20), n (%) (N  = 20), n (%) n (%)
Patient delay 
 Patient duration of symptoms <3 months 12 (60) 17 (85) 29 (73) 
 Patient duration of symptoms ö3 months 8 (40) 3 (15) 11 (28)
Provider delay 
 Provider duration of symptoms <3 months 10 (50) 6 (30) 16 (40) 
 Provider duration of symptoms ö3 months 10 (50) 14 (70) 24 (60)
Table 3. Frequency of trigger symptoms for patients diagnosed 
via symptomatic presentation (includes all symptoms, including 
those of patients who reported more than one symptom, therefore 
columns do not add up to 40)
 Patients aged Patients aged All patients 
 18–24 years 25–29 years (N  = 40), 
 (N  = 20), n (%) (N  = 20), n (%) n (%)
Symptom 
 Any bleeding symptom 16 (80.0) 17 (85.0) 33 (82.5) 
 Bleeding between periods 5 (25.0) 6 (30.0) 11 (27.5) 
 Bleeding after sex 10 (50.0) 9 (45.0) 19 (47.5) 
 Bleeding during pregnancy – 3 (15.0) 3 (7.5) 
 Change in periods 2 (10.0) 1 (5.0) 3 (7.5) 
 Painful sex 3 (15.0) 2 (10.0) 5 (12.5) 
 Vaginal discharge 3 (15.0) 4 (20.0) 7 (17.5) 
 Abdominal pain 2 (10.0) 3 (15.0) 5 (12.5)
Percentages are calculated based on the total number of patients diagnosed via symptomatic presentation. 
The most common trigger symptom is in bold.
delay after symptomatic presentation. 
For three of these, however, the first 
attendance had been at a sexual health 
clinic, meaning there were no records of the 
relevant consultations. For the remaining 
18, a consultation could be identified in the 
GP notes matching the first attendance 
reported by the patient (in terms of similar 
symptoms and date) for 10 (56%) patients. 
For six of these patients, the delay occurred 
in primary care. For two of these, there 
was no record of visualising the cervix. 
Both had presented with intermenstrual 
bleeding (one also had postcoital bleeding) 
and both had tested negative for genital 
infection. In both of these patient’s records, 
the records documented advice to return if 
symptoms continued; however, for both, the 
subsequent attendance was 5–6 months 
later.
For the other four patients with primary 
care delay, visualisation of the cervix 
was recorded: normal in two, cervical 
polyp for one, and ‘cervical bleeding on 
contact’ for one. The notes recorded tests 
for genital infections in all four patients, 
of whom three had positive results; one 
chlamydia and two bacterial vaginosis. 
For three of these patients, 2–6 months 
elapsed between first presentation and the 
next attendance. Advice to re-attend was 
documented in only one of the patient’s GP 
notes. The remaining patient was referred 
routinely to gynaecology after 3 months of 
re-presenting with heavy intermenstrual 
bleeding.
For the remaining four patients, there 
was secondary care delay. In three of these, 
no malignancy was found on the initial 
biopsy in secondary care. The remaining 
patient waited 8–10 weeks to be seen in 
gynaecology, then colposcopy.
Patients who were pregnant
Three patients (8%) diagnosed via 
symptomatic presentation were pregnant 
at the time of first presentation. All 
three had reported bleeding during their 
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Table 4. Possible risk factors for patient and provider delay for patients diagnosed via symptomatic 
presentation (n = 40)
 Patients with  Patients without  Patients with Patients without 
 patient delay patient delay Odds ratio provider delay provider delay Odds ratio 
 (n  = 11), n (%) (n  = 29), n (%) (95% CI) (n  = 24), n (%) (n  = 16), n (%) (95% CI)
Symptom 
 Nature of trigger symptom (n  = 40) 
 Any bleeding symptom 9 (82) 24 (83) 0.9 (0.1 to 11.5) 20 (83) 13 (81) 1.2 (0.1 to 8.1) 
 Bleeding between periods 2 (18) 9 (31) 0.5 (0.0 to 3.2) 6 (25) 5 (31) 0.7 (0.1 to 3.9) 
 Bleeding after sex 6 (55) 13 (45) 1.5 (0.3 to 7.6) 11 (46) 8 (50) 0.8 (0.2 to 3.6) 
 Painful sex 1 (9) 4 (14) 0.6 (0.0 to 7.5) 3 (13) 2 (13) 1.0 (0.1 to 13.4) 
 Vaginal discharge 3 (27) 4 (14) 2.3 (0.3 to 17.0) 3 (13) 4 (25) 0.4 (0.1 to 3.1) 
 Did not think the trigger symptom was 
   serious at the time 10 (91) 23 (79) 2.6 (0.3 to 131.8) – –
Demographic factors 
 Had children 7 (64) 12 (41) 2.5 (0.5 to 14.0) – – 
 Left school aged õ16 years  3 (27) 5 (17) 1.8 (0.2 to 11.8) – –
Other gynaecological factors 
 Using hormonal contraception or  
   intrauterine device a 8 (89) 17 (81) 1.9 (0.1 to 104.1) 15 (88) 10 (77) 2.3 (0.2 to 30.7) 
 Pregnant at first attendance (n  = 3) b 0 3 (10) – 3 (13) 0 –
Reported knowledge of cervical cancer  
symptoms before diagnosis 
 Did not know what the symptoms of  
   cervical cancer were  10 (91) 20 (69) 4.5 (0.5 to 216.6) – –
Barriers to symptomatic presentationc 
 Feeling too embarrassed 6 (55) 8 (29) 3.0 (0.6 to 16.2) – – 
 Worrying about not seeing a female doctor 5 (45) 8 (29) 2.1 (0.4 to 11.0) – – 
 Finding it difficult to get an appointment 6 (55) 10 (37) 2.0 (0.4 to 10.7) – – 
 Not wanting to waste the GP’s time 5 (45) 11 (39) 1.3 (0.2 to 6.5) – – 
 Being too busy to make an appointment 6 (55) 14 (48) 1.3 (0.3 to 6.6) – – 
 Worrying about what the GP might find 2 (18) 5 (18) 1.0 (0.1 to 7.8) – –
aPercentages calculated excluding pregnant patients from the denominator. bPercentages calculated using the number of pregnant patients as the denominator. cMissing 
values for some patients, therefore percentages were calculated using the number of patients who answered each question as the denominator.
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pregnancy, presented straight away, and 
were managed in secondary care. Two 
of these patients had a colposcopy while 
pregnant, but no malignancy was identified 
on biopsy. All three patients continued to 
have symptoms throughout pregnancy 
and after giving birth, and were eventually 
diagnosed 9–10 months after presenting 
with their trigger symptom (stages 1b1, 2b, 
and 3b).
Patients diagnosed via an abnormality 
detected on NHS Cervical Screening 
Programme 
Most patients diagnosed via routine cervical 
screening had microinvasive cancer (55/86, 
64%). Most (72/86; 84%) reported symptoms 
that started before the diagnostic screening 
test, most commonly vaginal discharge 
(n = 39), postcoital bleeding (n = 38), and 
intermenstrual bleeding (n = 23).
More patients diagnosed via screening 
reported longstanding symptoms (>2 years) 
than those diagnosed via symptomatic 
presentation (for example, postcoital 
bleeding 42% [16/38] versus 17% [5/30]; 
P = 0.02, intermenstrual bleeding 43% 
[10/23] versus 18% [4/22]; P = 0.07). Also, 
abnormal vaginal bleeding was less severe 
in screen-detected patients with fewer 
reporting flooding or clots (19% [10/53] 
versus 44% [17/39], P = 0.01).
About half of the patients diagnosed via 
screening who reported symptoms (35/72; 
49%) reported that they had presented with 
these to a health professional. Their most 
common symptoms were abnormal vaginal 
bleeding (16/35, 46%) (mainly postcoital 
bleeding [10/35, 29%]) and dyspareunia 
(10/35, 29%). Median duration of symptoms 
from first symptom to diagnosis was 
29.6 months (IQR 15.4–87.1 months).
The remaining 37 patients who reported 
symptoms said they had not sought help 
for their symptoms. Their most common 
symptoms were vaginal discharge (16/37, 
43%), postcoital bleeding (13/37, 35%) and 
abdominal pain and fatigue (both 12/37, 
32%). Median duration of symptoms from 




Among 128 young patients diagnosed with 
cervical cancer aged 18–29 years, 40 were 
diagnosed via symptomatic presentation. 
These patients were more likely to have 
more advanced cancers than patients who 
were diagnosed via screening, although 
very few patients had stage 2 or above. Of 
the patients eligible for screening, one-
fifth were diagnosed via symptomatic 
presentation.
Most patients presenting 
symptomatically had abnormal vaginal 
bleeding, most commonly postcoital 
bleeding. One-quarter of these delayed 
presentation for ö3 months after onset 
of symptoms: this was more common in 
those aged <25 years. Over half reported 
gynaecological symptoms some time 
before the symptom that caused them to 
present: this may have been an opportunity 
for earlier diagnosis. Vaginal discharge was 
the most common of these.
Provider delay was reported frequently. 
No conclusive evidence was found about 
risk factors for provider delay, although not 
all patients with provider delay had had their 
cervix visualised in primary care and many 
had co-existing genital infection. There was 
also some evidence that some delay in 
primary care may be because of patients 
not re-attending after first presentation 
promptly despite persistent symptoms.
Strengths and limitations
To the authors’ knowledge, this study has 
provided the most detailed information 
to date on the nature and duration of 
symptoms for young females with cervical 
cancer. The methods and reporting are 
consistent with the Aarhus statement on 
studies of early cancer diagnosis.20 In the 
present study, a high identification rate was 
achieved and the population was broadly 
representative of patients diagnosed with 
cervical cancer in England over a similar 
period. Another key strength was the high 
quality of the data collected. By using an 
interview-based measure, which was 
developed and tested in young patients with 
cervical cancer,15 it was possible to record 
complicated data systematically.
The possibility of recall error cannot 
be ruled out. This was minimised using 
calendar anchoring and collaborative 
completion of a timeline detailing the events 
that led to diagnosis.15 In addition, most 
patients were interviewed within 6 months 
of diagnosis. 
Identification of risk factors for delays in 
cervical cancer diagnosis was limited by 
small study numbers, which is inevitable 
with rare diseases. A study with sufficient 
power to find statistically significant risk 
factors for delay in presentation would have 
to recruit patients for years.
Comparison with existing literature
The present findings are consistent with 
research showing that cervical cancer 
symptom awareness among young British 
Funding
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Julietta Patnick (Director of Cancer Screening 
Programmes in England) commented on and 
approved the final version of the manuscript, 
but was not involved in the development 
of methods, data collection, analysis, or 
interpretation of the data. 
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females is low.24 An online YouGov survey 
of 2726 females in the UK found that 20% 
of 18–24-year-olds said that they would not 
seek help for bleeding during sex (M Durrant, 
personal communication, August 2013). 
A systematic review that examined the 
risk factors for delayed presentation in 
cancer found that non-recognition of the 
severity of symptoms, symptom type (for 
example, vague), infrequent care-seeking, 
and fear were the predominant risk factors 
for delayed presentation for gynaecological 
cancers.25
Implications for research and practice
The study confirms the findings of case 
reports suggesting that patients <25 years 
often delay presentation with cervical 
cancer and have more advanced stage. This 
supports the idea that earlier presentation 
could improve outcomes in this group.
Although this study was small, it provides 
preliminary data that could be used to 
inform interventions to promote earlier 
presentation in this group by ensuring 
that they set out the possible symptoms 
of cervical cancer clearly (framing these 
in particular for young females of low 
education, who are at higher risk of cervical 
cancer in any case),26 perhaps emphasising 
that other priorities, embarrassment, and 
worry about wasting the doctor’s time 
should not deter them from presenting, 
and that they will be able to see a female 
doctor if they wish.
The challenge is that gynaecological 
symptoms in young females are very 
common, and promoting early presentation 
for these symptoms could lead to a large 
increase in attendances in primary care 
and unnecessary anxiety in females who do 
not have cancer (or cervical abnormalities). 
For females aged 15–29 years, at least 
1.6% presented to primary care with 
intermenstrual bleeding, 0.5% with 
postcoital bleeding, and 1.3% with vaginal 
discharge in any 1-year period.11
Although most screen-detected patients 
reported symptoms, a high proportion of 
these were longstanding yet most had early 
stage cancer. This implies that some of 
their symptoms were unlikely to have been 
related to their cancer.
The present data suggest that pregnancy 
at the time of presentation may be a risk 
factor for provider delay; however, these 
patients appear to be difficult to diagnose 
given that even at colposcopy (including 
biopsy), malignancy was not easily identified.
The data from primary care records were 
too sparse to be able to draw any firm 
conclusions about the quality of management 
of gynaecological symptoms in primary care, 
although patients may not be having their 
cervix visualised when they present with 
abnormal vaginal bleeding, despite the UK 
guidance on this.17 Furthermore, patients 
may delay re-attending after the first 
presentation, and re-attendance should be 
strongly advised if their symptoms persist.
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Appendix 1. Characteristics of patients aged 18–29 years diagnosed 
with cervical cancer identified over the study period who responded, 
who were interviewed versus not interviewed and patients identified 
over the study period versus patients aged 18–29 years diagnosed 
with cervical cancer in England in 2010
   Patients Patients 
 Patients Patients not diagnosed identified over 
 interviewed interviewed in 2010 a study period 
 (N  = 128), n (%) (N  = 206), n (%) (N  = 352), n (%)  (N  = 334), n (%)
Age at diagnosis, years 
 18–24  22 (17) 10 (5) 45 (13) 32 (10) 
 25–29  106 (83) 196 (95) 307 (87) 302 (90)
FIGO stage b 





 1b 52 (41) 56 (27)   
 2 6 (5) 12 (6) 22 (7) 17 (5) 
 3 3 (2) 1 (0.5) 6 (2) 4 (1) 
 4 0 2 (1) 7 (2) 7 (2) 
 Missing 0 8 (3) 50 8 
Histology 
 Squamous cell carcinoma 93 (73) 170 (83) 276 (78) 263 (79) 
 Adenocarcinoma 28 (22) 28 (14) 47 (13) 56 (17) 
 Other 7 (5) 6 (3) 29 (8) 13 (4) 
 Missing – 2 (1) – 2 (1)
Strategic Health Authority 
 North East 19 (9) 7 (5) 28 (8) 26 (8) 
 North West 35 (17) 17 (13) 64 (18) 52 (16) 
 Yorkshire & Humber 38 (18) 24 (19) 49 (14) 62 (19) 
 East Midlands 19 (9) 14 (11) 34 (10) 33 (10) 
 West Midlands 27 (13) 15 (12) 38 (11) 42 (13) 
 East of England 21 (10) 11 (9) 33 (9) 32 (10) 
 London 14 (7) 15 (12) 27 (8) 26 (8) 
 South East Coast 5 (2) 4 (2) 17 (5) 20 (6) 
 South Central 14 (7) 7 (5) 21 (6) 21 (6) 
 South West 14 (7) 6 (5) 41 (12) 20 (6)
Some percentages do not add up to 100% due to rounding. aData supplied by Trent Cancer Registry from the 
2010 National Cancer Data Repository. bFor patients diagnosed in England in 2010 and patients identified over 
the study period, percentages were calculated using the number of patients with known FIGO stage as the 
denominator because of the high proportion of patients with missing stage. FIGO = International Federation of 
Gynecology and Obstetrics.
